Although CD19 CAR‐T cell therapy has achieved amazing overall CR rates in patients with R/R B‐ALL and B cell lymphoma, 40%–60% of CR patients eventually experience relapse [5]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.